The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

• Status: Unknown status
• Trial end date: 2021-09-30
• Target enrollment: 0
• Participant gender: All

Summary

No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-AF study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in non-valvular atrial fibrillation across Danish hospitals and cardiology clinics.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Danish Heart Foundation
• Collaborator: Danish Society of Cardiology
• Treatments: Anticoagulants; Apixaban; Dabigatran; Edoxaban; Rivaroxaban

Criteria

Inclusion Criteria:

• A diagnosis of atrial fibrillation in outpatient clinic or as discharge diagnosis after hospitalization.

• A claimed prescription of a NOAC from a Danish pharmacy within 14 days of discharge or outpatient clinic visit.

Exclusion Criteria:

• A prescription of a NOAC within 90 days prior to hospitalization or outpatient clinic visit for AF.

• Presence of a mechanic cardiac valve prosthesis.

• Patients with NOAC preference apart from preference consistent with current cluster randomized NOAC.

• Other contraindications mentioned in the "Summary of Product Characteristics" for the respective NOAC.